GLP-1 obesity drugs set to become access battleground in lower-income countries
Published 3 d ago1 sourceEvidence: Reported
Novo Nordisk presented study data on cagrisema, a fixed-dose combination of kagrilintid and semaglutide, in adults with overweight or obesity at Obesity Week. The presentation precedes a crucial FDA decision, but the data's specifics and regulatory implications remain unclear. This matters as cagrisema could be a major growth driver for Novo, with market impact contingent on the FDA's ruling.
AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works
Locations
Entities
Published 3 d ago1 sourceEvidence: Reported
Published 21 h ago1 sourceEvidence: Reported
Published 2 d ago1 sourceEvidence: Reported
Published 2 d ago1 sourceEvidence: Reported
Published 1 d ago1 sourceEvidence: Reported
Published 2 d ago1 sourceEvidence: Reported
Published 2 d ago1 sourceEvidence: Reported
Published 18 h ago1 sourceEvidence: Reported